{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:17:07Z","timestamp":1791418627697,"version":"4.3.3"},"reference-count":29,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1999,7]]},"abstract":" PURPOSE: A prospective, nonrandomized, multicenter, open feasibility study of cisplatin and docetaxel as first-line chemotherapy in International Federation of Gynecology and Obstetrics (FIGO) stage IC-IV epithelial ovarian cancer was conducted. The primary end point was the incidence of severe fluid retention that necessitated treatment withdrawal. <\/jats:p> PATIENTS AND METHODS: Cisplatin and docetaxel were administered every 3 weeks for six planned cycles, with a 5-day prophylactic dexamethasone regimen (8 mg two times per day). One hundred patients (median age, 53 years; range, 24 to 71 years) received a total of 512 cycles of chemotherapy in two cohorts: cohort 1, 49 patients, 258 cycles (cisplatin 75 mg\/m2<\/jats:sup> and docetaxel 75 mg\/m2<\/jats:sup>); cohort 2, 51 patients, 254 cycles (cisplatin 75 mg\/m2<\/jats:sup> and docetaxel 85 mg\/m2<\/jats:sup>). <\/jats:p> RESULTS: No patients were taken off study because of fluid retention. Sixty-six patients completed six cycles of protocol therapy; 16 stopped early because of toxicity (neurotoxicity in six patients, nephrotoxicity in three, neutropenia in two, and hypersensitivity, diarrhea and vomiting, skin rash, clinical deterioration, and patient's wishes in one patient each). Grade 3\/4 neutropenia was observed in more than 75% of patients and seemed to be cumulative. Patients in cohort 2 had significantly more severe neutropenia and lethargy than those in cohort 1. In addition, there were five treatment-related deaths in cohort 2 (three neutropenia and two upper gastrointestinal hemorrhage). Neurotoxicity (mainly sensory, > grade 1) was observed in 23 patients. The overall clinical response rate was 69% (complete response, 38%; partial response, 31%); CA-125 response rate was 73%. Median progression-free survival for the group was 12 months. <\/jats:p> CONCLUSION: Cisplatin and docetaxel can be administered at doses of 75 mg\/m2<\/jats:sup> and 75 mg\/m2<\/jats:sup>, respectively, every 3 weeks, and the utility of this regimen is not limited by fluid retention. However, 33 of 100 patients were unable to complete the planned six cycles, which may explain, in part, the poor overall progression-free survival. Increasing the docetaxel dose to 85 mg\/m2<\/jats:sup> adds unacceptable hematologic toxicity and potential risks to the patient. <\/jats:p>","DOI":"10.1200\/jco.1999.17.7.2069","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:31:04Z","timestamp":1487917864000},"page":"2069-2069","source":"Crossref","is-referenced-by-count":61,"title":["Docetaxel and Cisplatin in Combination as First-Line Chemotherapy for Advanced Epithelial Ovarian Cancer"],"prefix":"10.1200","volume":"17","author":[{"given":"P. A.","family":"Vasey","sequence":"first","affiliation":[{"name":"From the Cancer Research Campaign Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow; Belfast City Hospital, Belfast; Bristol Oncology Centre, Bristol; Airedale General Hospital, Steeton, West Yorkshire; Weston Park Hospital, Sheffield; Hammersmith Hospital, London; Stobhill Hospital, Springburn, Glasgow, United Kingdom; and Rh\u00f4ne-Poulenc Rorer, Antony, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Paul","sequence":"additional","affiliation":[{"name":"From the Cancer Research Campaign Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow; Belfast City Hospital, Belfast; Bristol Oncology Centre, Bristol; Airedale General Hospital, Steeton, West Yorkshire; Weston Park Hospital, Sheffield; Hammersmith Hospital, London; Stobhill Hospital, Springburn, Glasgow, United Kingdom; and Rh\u00f4ne-Poulenc Rorer, Antony, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Birt","sequence":"additional","affiliation":[{"name":"From the Cancer Research Campaign Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow; Belfast City Hospital, Belfast; Bristol Oncology Centre, Bristol; Airedale General Hospital, Steeton, West Yorkshire; Weston Park Hospital, Sheffield; Hammersmith Hospital, London; Stobhill Hospital, Springburn, Glasgow, United Kingdom; and Rh\u00f4ne-Poulenc Rorer, Antony, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. J.","family":"Junor","sequence":"additional","affiliation":[{"name":"From the Cancer Research Campaign Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow; Belfast City Hospital, Belfast; Bristol Oncology Centre, Bristol; Airedale General Hospital, Steeton, West Yorkshire; Weston Park Hospital, Sheffield; Hammersmith Hospital, London; Stobhill Hospital, Springburn, Glasgow, United Kingdom; and Rh\u00f4ne-Poulenc Rorer, Antony, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. S.","family":"Reed","sequence":"additional","affiliation":[{"name":"From the Cancer Research Campaign Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow; Belfast City Hospital, Belfast; Bristol Oncology Centre, Bristol; Airedale General Hospital, Steeton, West Yorkshire; Weston Park Hospital, Sheffield; Hammersmith Hospital, London; Stobhill Hospital, Springburn, Glasgow, United Kingdom; and Rh\u00f4ne-Poulenc Rorer, Antony, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. P.","family":"Symonds","sequence":"additional","affiliation":[{"name":"From the Cancer Research Campaign Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow; Belfast City Hospital, Belfast; Bristol Oncology Centre, Bristol; Airedale General Hospital, Steeton, West Yorkshire; Weston Park Hospital, Sheffield; Hammersmith Hospital, London; Stobhill Hospital, Springburn, Glasgow, United Kingdom; and Rh\u00f4ne-Poulenc Rorer, Antony, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Atkinson","sequence":"additional","affiliation":[{"name":"From the Cancer Research Campaign Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow; Belfast City Hospital, Belfast; Bristol Oncology Centre, Bristol; Airedale General Hospital, Steeton, West Yorkshire; Weston Park Hospital, Sheffield; Hammersmith Hospital, London; Stobhill Hospital, Springburn, Glasgow, United Kingdom; and Rh\u00f4ne-Poulenc Rorer, Antony, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Graham","sequence":"additional","affiliation":[{"name":"From the Cancer Research Campaign Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow; Belfast City Hospital, Belfast; Bristol Oncology Centre, Bristol; Airedale General Hospital, Steeton, West Yorkshire; Weston Park Hospital, Sheffield; Hammersmith Hospital, London; Stobhill Hospital, Springburn, Glasgow, United Kingdom; and Rh\u00f4ne-Poulenc Rorer, Antony, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Crawford","sequence":"additional","affiliation":[{"name":"From the Cancer Research Campaign Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow; Belfast City Hospital, Belfast; Bristol Oncology Centre, Bristol; Airedale General Hospital, Steeton, West Yorkshire; Weston Park Hospital, Sheffield; Hammersmith Hospital, London; Stobhill Hospital, Springburn, Glasgow, United Kingdom; and Rh\u00f4ne-Poulenc Rorer, Antony, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Coleman","sequence":"additional","affiliation":[{"name":"From the Cancer Research Campaign Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow; Belfast City Hospital, Belfast; Bristol Oncology Centre, Bristol; Airedale General Hospital, Steeton, West Yorkshire; Weston Park Hospital, Sheffield; Hammersmith Hospital, London; Stobhill Hospital, Springburn, Glasgow, United Kingdom; and Rh\u00f4ne-Poulenc Rorer, Antony, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Thomas","sequence":"additional","affiliation":[{"name":"From the Cancer Research Campaign Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow; Belfast City Hospital, Belfast; Bristol Oncology Centre, Bristol; Airedale General Hospital, Steeton, West Yorkshire; Weston Park Hospital, Sheffield; Hammersmith Hospital, London; Stobhill Hospital, Springburn, Glasgow, United Kingdom; and Rh\u00f4ne-Poulenc Rorer, Antony, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Davis","sequence":"additional","affiliation":[{"name":"From the Cancer Research Campaign Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow; Belfast City Hospital, Belfast; Bristol Oncology Centre, Bristol; Airedale General Hospital, Steeton, West Yorkshire; Weston Park Hospital, Sheffield; Hammersmith Hospital, London; Stobhill Hospital, Springburn, Glasgow, United Kingdom; and Rh\u00f4ne-Poulenc Rorer, Antony, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. P.H.","family":"Eggleton","sequence":"additional","affiliation":[{"name":"From the Cancer Research Campaign Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow; Belfast City Hospital, Belfast; Bristol Oncology Centre, Bristol; Airedale General Hospital, Steeton, West Yorkshire; Weston Park Hospital, Sheffield; Hammersmith Hospital, London; Stobhill Hospital, Springburn, Glasgow, United Kingdom; and Rh\u00f4ne-Poulenc Rorer, Antony, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. B.","family":"Kaye","sequence":"additional","affiliation":[{"name":"From the Cancer Research Campaign Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow; Belfast City Hospital, Belfast; Bristol Oncology Centre, Bristol; Airedale General Hospital, Steeton, West Yorkshire; Weston Park Hospital, Sheffield; Hammersmith Hospital, London; Stobhill Hospital, Springburn, Glasgow, United Kingdom; and Rh\u00f4ne-Poulenc Rorer, Antony, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-2069","doi-asserted-by":"crossref","unstructured":"Yancik R: Ovarian cancer: Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71:517,1993-523, (suppl 2)","DOI":"10.1002\/cncr.2820710205"},{"key":"R3-2069","doi-asserted-by":"crossref","unstructured":"Neijt JP, ten Bokkel Huinink WW van der Berg MEL, et al: Long term survival in ovarian cancer. Eur J Cancer 17:1367,1991-1372,","DOI":"10.1016\/0277-5379(91)90011-2"},{"key":"R4-2069","doi-asserted-by":"publisher","DOI":"10.1021\/ja00738a045"},{"key":"R5-2069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.9.1748"},{"key":"R6-2069","doi-asserted-by":"crossref","unstructured":"Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 22:665,1979-667,","DOI":"10.1038\/277665a0"},{"key":"R7-2069","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.3.1561"},{"key":"R8-2069","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.91.2.479"},{"key":"R9-2069","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601043340101"},{"key":"R12-2069","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059220"},{"key":"R13-2069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2654"},{"key":"R14-2069","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.4.288"},{"key":"R16-2069","doi-asserted-by":"publisher","DOI":"10.1021\/jm00107a017"},{"key":"R17-2069","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199204000-00008"},{"key":"R18-2069","unstructured":"Alberts DS, Garcia D, Fanta P, et al: Comparative cytotoxicities of Taxol and Taxotere in vitro against fresh human ovarian cancers. Proc Am Soc Clin Oncol 11:226,1992, (abstr 719)"},{"key":"R19-2069","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199506000-00001"},{"key":"R20-2069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.12.2886"},{"key":"R23-2069","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)00363-8"},{"key":"R24-2069","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1993.1250"},{"key":"R27-2069","unstructured":"Francis P, Hakes T, Schneider J, et al: Phase II study of docetaxel (Taxotere) in advanced platinum-refractory ovarian cancer. Proc Am Soc Clin Oncol 13:260,1994, (abstr 825)"},{"key":"R28-2069","unstructured":"Aapro MS, Pujade-Lauraine E, Lhomme C, et al: EORTC Clinical Screening Group: Phase II study of Taxotere in ovarian cancer. Ann Oncol 5:202,1994, (suppl 5)"},{"key":"R29-2069","unstructured":"Kavanagh J, Kudelka A, Freedman R, et al: Taxotere (docetaxel): Activity in platinum refractory ovarian cancer and amelioration of toxicity. Proc Am Soc Clin Oncol 13:237,1994, (abstr 732)"},{"key":"R30-2069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.9.3149"},{"key":"R31-2069","doi-asserted-by":"crossref","unstructured":"Cassidy J, Paul J, Soukop M, et al: Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatinum. Cancer Chemother Pharmacol 41:161,1988-166,","DOI":"10.1007\/s002800050723"},{"key":"R32-2069","doi-asserted-by":"crossref","unstructured":"Miller AB, Hoogstraten S, Staquet M, et al: Reporting results of cancer treatment. Cancer 74:207,1981-214,","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"R33-2069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.5.1545"},{"key":"R34-2069","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199608000-00021"},{"key":"R36-2069","doi-asserted-by":"publisher","DOI":"10.2307\/2530528"},{"key":"R38-2069","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1993.488"},{"key":"R39-2069","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690046"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1999.17.7.2069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:34:30Z","timestamp":1653514470000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1999.17.7.2069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1999,7]]}},"alternative-id":["10.1200\/JCO.1999.17.7.2069"],"URL":"https:\/\/doi.org\/10.1200\/jco.1999.17.7.2069","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,7]]}}}